Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Pharmaceuticals Dongying (Jiangsu) Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, allowing it to commence production [1] Group 1: Drug Approval - The Minoxidil topical solution has been approved for production as a Class A over-the-counter drug in accordance with the Drug Administration Law of the People's Republic of China [1] - The drug was originally developed by Johnson & Johnson, with the 2% formulation launched in the U.S. in 1988 and the 5% formulation in 1997 [1] Group 2: Indications and Usage - The 2% formulation is indicated for the treatment of male pattern baldness and alopecia areata, while the 5% formulation is restricted to male use for the same conditions [1] Group 3: Development and Competition - Shanghai Pharmaceuticals Dongying submitted the registration application for the drug to the National Medical Products Administration in January 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 6.56 million in the research and development of this drug [1] - Major domestic manufacturers of this drug include Shanxi Zhendong Anxin Biopharmaceutical, Sichuan Meida Kanghua Pharmaceutical, and Shandong Jingwei Pharmaceutical [1]

格隆汇12月5日丨上海医药(02607.HK)公布，2021 年 10 月 8 日，公司全资子公司上海上药信谊药厂有 限公司(以下简称"上药信谊")与贵州生诺生物科技有限公司(以下简称"贵州生诺")及全资子公司江苏太瑞 生诺生物医药科技有限公司(以下简称"江苏生诺")签署了新型抑酸剂 X842 项目(以下简称"X842")的《生 产、销售及开发合作协议》(以下简称"《原合作协议》")，上药信谊获得了 X842 原料药及制剂在中国 区域的独家委托生产和所有适应症的工业销售权。 2025 年 11 月 18 日，基于对外部市场的综合评估，同时考虑各方整体经营发展规划，经友好协商，上 药信谊与贵州生诺、江苏生诺及贵州生诺全资子公司上海生诺医药科技有限公司(三者合并简称"生诺生 物")签订了《生产、销售及开发合作协议之终止协议》(以下简称"《终止协议》")，主要内容如下： 3、适用中国法律，争议解决方式同《原合作协议》，即中国国际经济贸易仲裁委员会仲裁，仲裁地点 在北京。 2025 年 12 月 5 日，上药信谊收到生诺生物返还的 1.1 亿元首付款及开发注册里程碑费用，《原合作协 议》自动终止且对各方不再具有法律约 ...

2、生诺生物于《终止协议》生效后45个工作日内按照年化3%利率向上药信谊支付1.1亿元首付款及开 发注册里程碑费用对应的资金占用费。 3、适用中国法律，争议解决方式同《原合作协议》，即中国国际经济贸易仲裁委员会仲裁，仲裁地点 在北京。 2025年12月5日，上药信谊收到生诺生物返还的1.1亿元首付款及开发注册里程碑费用，《原合作协议》 自动终止且对各方不再具有法律约束力。 智通财经APP讯，上海医药(02607)发布公告，2021年10月8日，上海医药集团股份有限公司(以下简 称"上海医药"或"公司")全资子公司上海上药信谊药厂有限公司(以下简称"上药信谊")与贵州生诺生物科 技有限公司(以下简称"贵州生诺")及全资子公司江苏太瑞生诺生物医药科技有限公司(以下简称"江苏生 诺")签署了新型抑酸剂X842项目(以下简称"X842")的《生产、销售及开发合作协议》(以下简称"《原合 作协议》")，上药信谊获得了X842原料药及制剂在中国区域(包括香港、澳门及台湾)的独家委托生产和 所有适应症的工业销售权。 2025年11月18日，基于对外部市场的综合评估，同时考虑各方整体经营发展规划，经友好协商，上药信 谊与贵州 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * * 僅供識別 （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於與貴州生諾生物科技有限公司合作協議終止的公 告》、《上海醫藥集團股份有限公司關於米諾地爾搽劑獲得批准生產的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 12 月 6 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、 ...

证券代码：601607 证券简称：上海医药 编号：临 2025-111 上海医药集团股份有限公司 药品批准文号：国药准字 H20256053、H20256054 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。同意本品按甲类非处 方药管理。 二、该药品相关的信息 关于米诺地尔搽剂获得批准生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上药东英（江 苏）药业有限公司（以下简称"上药东英"）的米诺地尔搽剂（以下简称"该药 品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品注册 证书》（证书编号：2025S03530、2025S03531），该药品获得批准生产。 一、该药品基本情况 药品名称：米诺地尔搽剂 剂型：搽剂 规格：2％（60 毫升：1.2 克）；5％（60 毫升：3.0 克） 注册分类：化学药品 3 类 米诺地尔搽剂最早由强生公司开发，2%规格于 1988 年在美国 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-110 上海医药集团股份有限公司 关于与贵州生诺生物科技有限公司合作协议终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、基本情况 （一）《合作协议》签署情况 2021 年 10 月 8 日，上海医药集团股份有限公司（以下简称"上海医药"或 "公司"）全资子公司上海上药信谊药厂有限公司（以下简称"上药信谊"）与贵 州生诺生物科技有限公司（以下简称"贵州生诺"）及全资子公司江苏太瑞生诺 生物医药科技有限公司（以下简称"江苏生诺"）签署了新型抑酸剂 X842 项目 （以下简称"X842"）的《生产、销售及开发合作协议》（以下简称"《原合作协 议》"），上药信谊获得了 X842 原料药及制剂在中国区域（包括香港、澳门及台 湾）的独家委托生产和所有适应症的工业销售权（详见公司公告临 2021-081 号）。 （二）《原合作协议》终止 2025 年 11 月 18 日，基于对外部市场的综合评估，同时考虑各方整体经营 发展规划，经友好协商，上药信谊与贵州 ...

Core Viewpoint - Shanghai Pharmaceuticals announced the termination of the cooperation agreement related to the X842 project with Shengnuo Biotech, which will not significantly impact the company's financial and operational performance [1] Group 1 - In 2021, Shanghai Pharmaceuticals' wholly-owned subsidiary, Shanghai Pharmaceuticals Xinyi, signed an original cooperation agreement with Guizhou Shengnuo and Jiangsu Shengnuo for the X842 project, granting exclusive production and sales rights [1] - On November 18, 2025, Shanghai Pharmaceuticals Xinyi and Shengnuo Biotech signed a termination agreement, which became effective upon the receipt of a refund of 110 million yuan [1] - The original cooperation agreement automatically terminated on December 5, 2025, after the receipt of the refund [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Dongying (Jiangsu) Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, allowing for production approval [1] Group 1: Product Details - Minoxidil topical solution was originally developed by Johnson & Johnson, with the 2% formulation launched in the U.S. in 1988 and the 5% formulation in 1997 [1] - The 2% formulation is indicated for the treatment of androgenetic alopecia and alopecia areata, while the 5% formulation is restricted to male use for the same conditions [1] Group 2: Regulatory and Financial Aspects - The registration application for the drug was submitted to the National Medical Products Administration in January 2024 and was accepted [1] - As of the announcement date, the company has invested approximately RMB 6.56 million in research and development for this product [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Dongying (Jiangsu) Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, allowing for production approval [1] Group 1: Product Details - Minoxidil topical solution was originally developed by Johnson & Johnson, with the 2% formulation launched in the U.S. in 1988 and the 5% formulation in 1997 [1] - The 2% formulation is indicated for the treatment of male pattern baldness and alopecia areata, while the 5% formulation is restricted to male use for the same conditions [1] Group 2: Regulatory and Financial Information - In January 2024, Shanghai Pharmaceuticals Dongying submitted a registration application for the product to the National Medical Products Administration, which was accepted [1] - As of the announcement date, the company has invested approximately RMB 6.56 million in research and development for this product [1]

Core Insights - Shanghai has launched new national-level platforms aimed at enhancing innovation in traditional Chinese medicine and integrated circuit industries [1] Group 1: National Medical Innovation Platform - The National Medical Innovation Platform at Shanghai University of Traditional Chinese Medicine focuses on key technologies such as clinical advantage disease screening and intelligent pharmaceutical development [1] - Five leading companies in the industry, including Shanghai Pharmaceuticals and Shanghai Kaibao Pharmaceutical, have signed agreements to become the first batch of resident units [1] - The "Shanghai University of Traditional Chinese Medicine 7LAB Joint Laboratory" has been officially inaugurated [1] Group 2: Integrated Circuit Innovation Center - The "Integrated Circuit Packaging and Testing Talent Collaborative Innovation Center" is established through collaboration among government, academia, and enterprises [1] - This center aims to create a new high ground for talent integration in the integrated circuit industry [1] - The "Integrated Circuit Packaging and Testing Talent Integration Practice Base" has become a regional demonstration platform for industry-education collaboration, allowing students to engage in real production line environments and complete the entire process from design to testing [1]